Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medication safety

MHRA considering 'further action' after metformin diabetes drugs recalled in Singapore over impurities

Several metformin-containing medicines have been recalled in Singapore after reports of contamination with a probable human carcinogen, leading to testing of products in the EU.

Metformin pills

Source: Shutterstock.com

Metformin can be used to prevent and treat type 2 diabetes mellitus

The Medicines and Healthcare products Regulatory Agency (MHRA) is considering whether to take “further action” after metformin products were recalled in Singapore over reports of contamination.

Some 3 out of 46 metformin diabetes medicines have been recalled by Singapore’s Health Sciences Authority because they contained “trace amounts” of N-nitrosodimethylamine (NDMA), which it said “are above the internationally acceptable level”.

NDMA is classified as a probable human carcinogen, but is not thought to cause harm when ingested at very low levels.

However, the MHRA said in a statement, published on 6 December 2019, that because ”these metformin medicines are also available in Europe and outside the EU, the MHRA is working closely with the European Medicines Agency (EMA) and other regulatory authorities to determine whether any further action is required”.

The UK regulator advised patients to continue taking metformin as ”risks from not having adequate diabetes treatment far outweigh any possible effects of the low levels of NDMA” found in the medines.

It added that the levels of NDMA found in the recalled batches ”are very low and appear to be within or even below the range that people would normally be exposed from other sources, including food and water”.

The EMA said in a statement, published on the same day, that it has seen “no data indicating that EU metformin medicines are affected”.

But added: “Authorities in the EU are in the process of working with companies to test EU medicines and will provide further updates as more information becomes available.”

In September 2019, the EMA announced that it would start a review of ranitidine medicines after tests revealed that some products contained the impurity.

Then, in October 2019, the MHRA recalled some ranitidine products as a precautionary measure over the contamination.

In 2018, NDMA was also found in several blood pressure medicines, known as ‘sartans’, leading to recalls and an EMA review.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207448

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Statistics

    Pharmaceutical Statistics

    This book on basic statistics has been specifically written for pharmacy students.

    £33.00Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.